Compare Abbott India with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs SUN PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA SUN PHARMA ABBOTT INDIA/
SUN PHARMA
 
P/E (TTM) x 43.1 28.5 151.5% View Chart
P/BV x 12.4 2.5 502.3% View Chart
Dividend Yield % 0.6 0.6 86.0%  

Financials

 ABBOTT INDIA   SUN PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
SUN PHARMA
Mar-19
ABBOTT INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110679 900.1%   
Low Rs3,996375 1,064.5%   
Sales per share (Unadj.) Rs1,552.2121.1 1,281.3%  
Earnings per share (Unadj.) Rs188.813.4 1,411.5%  
Cash flow per share (Unadj.) Rs196.420.7 949.7%  
Dividends per share (Unadj.) Rs55.002.75 2,000.0%  
Dividend yield (eoy) %1.10.5 208.6%  
Book value per share (Unadj.) Rs796.6172.6 461.5%  
Shares outstanding (eoy) m21.252,399.26 0.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.34.4 74.8%   
Avg P/E ratio x26.839.4 67.9%  
P/CF ratio (eoy) x25.725.5 100.9%  
Price / Book Value ratio x6.33.1 207.7%  
Dividend payout %29.120.6 141.7%   
Avg Mkt Cap Rs m107,3761,264,650 8.5%   
No. of employees `0003.317.5 19.0%   
Total wages/salary Rs m3,93759,671 6.6%   
Avg. sales/employee Rs Th9,929.316,608.1 59.8%   
Avg. wages/employee Rs Th1,185.13,409.6 34.8%   
Avg. net profit/employee Rs Th1,207.71,833.8 65.9%   
INCOME DATA
Net Sales Rs m32,985290,659 11.3%  
Other income Rs m1,17010,255 11.4%   
Total revenues Rs m34,155300,914 11.4%   
Gross profit Rs m5,24563,076 8.3%  
Depreciation Rs m16217,533 0.9%   
Interest Rs m385,553 0.7%   
Profit before tax Rs m6,21550,246 12.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m2,2036,009 36.7%   
Profit after tax Rs m4,01232,093 12.5%  
Gross profit margin %15.921.7 73.3%  
Effective tax rate %35.412.0 296.4%   
Net profit margin %12.211.0 110.2%  
BALANCE SHEET DATA
Current assets Rs m22,655310,692 7.3%   
Current liabilities Rs m6,681173,396 3.9%   
Net working cap to sales %48.447.2 102.5%  
Current ratio x3.41.8 189.3%  
Inventory Days Days6599 65.4%  
Debtors Days Days29112 26.1%  
Net fixed assets Rs m835232,477 0.4%   
Share capital Rs m2132,399 8.9%   
"Free" reserves Rs m16,715411,691 4.1%   
Net worth Rs m16,928414,091 4.1%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m24,162646,938 3.7%  
Interest coverage x163.710.0 1,628.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.4 303.9%   
Return on assets %16.85.8 288.1%  
Return on equity %23.77.8 305.8%  
Return on capital %36.910.2 363.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36966,025 0.6%   
Fx outflow Rs m3,80738,610 9.9%   
Net fx Rs m-3,43827,415 -12.5%   
CASH FLOW
From Operations Rs m1,52721,965 7.0%  
From Investments Rs m-2,148-6,813 31.5%  
From Financial Activity Rs m-1,024-27,305 3.8%  
Net Cashflow Rs m-1,646-8,442 19.5%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.1 154.0%  
FIIs % 0.1 23.0 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.3 206.0%  
Shareholders   18,270 133,026 13.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 13, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS